Enrolling By Invitation PHASE3 INTERVENTIONAL 1-arm NCT06908226

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy

Sponsor: Longboard Pharmaceuticals

Conditions Developmental and Epileptic Encephalopathy

Interventions LP352

Updated 4 times since 2025 Last updated: Jan 2, 2026 Started: Feb 12, 2025 Primary completion: Nov 11, 2027 Completion: Dec 17, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Developmental and Epileptic Encephalopathy and is currently ongoing. Longboard Pharmaceuticals leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Enrolling By Invitation PHASE3
Aug 2025 — Feb 2026 [monthly]

Enrolling By Invitation PHASE3

Status: Recruiting → Enrolling By Invitation
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3

First recorded

Feb 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Longboard Pharmaceuticals

Data source: Longboard Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Belgrade, Serbia , Bethesda, United States , Gulf Breeze, United States , Heidelberg, Australia , Houston, United States , Little Rock, United States , Livingston, United States , Los Angeles, United States , Madrid, Spain and 5 more locations